See more : Sunny Electronics Corp. (004770.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Senseonics Holdings, Inc. (SENS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Senseonics Holdings, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Greatech Technology Berhad (0208.KL) Income Statement Analysis – Financial Results
- Odawara Engineering Co., Ltd. (6149.T) Income Statement Analysis – Financial Results
- Sichuan Langsha Holding Ltd. (600137.SS) Income Statement Analysis – Financial Results
- Athene Holding Ltd. 7.250% Fixe (ATHS) Income Statement Analysis – Financial Results
- Perma-Fix Environmental Services, Inc. (PESI) Income Statement Analysis – Financial Results
Senseonics Holdings, Inc. (SENS)
About Senseonics Holdings, Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.39M | 16.39M | 13.68M | 4.95M | 21.30M | 18.91M | 6.37M | 332.00K | 38.00K | 0.00 | 17.00K |
| Cost of Revenue | 19.30M | 13.66M | 14.49M | 22.32M | 40.75M | 27.06M | 9.76M | 660.00K | 118.00K | 0.00 | 5.00K |
| Gross Profit | 3.09M | 2.73M | -811.00K | -17.37M | -19.45M | -8.15M | -3.39M | -328.00K | -80.00K | 0.00 | 12.00K |
| Gross Profit Ratio | 13.81% | 16.63% | -5.93% | -350.90% | -91.30% | -43.07% | -53.11% | -98.80% | -210.53% | 0.00% | 70.59% |
| Research & Development | 48.75M | 39.72M | 27.22M | 20.41M | 38.43M | 31.86M | 30.74M | 26.35M | 18.25M | 12.88M | 13.79M |
| General & Administrative | 0.00 | 0.00 | 21.54M | 20.80M | 23.23M | 19.84M | 15.34M | 13.02M | 9.81M | 5.73M | 5.01M |
| Selling & Marketing | 0.00 | 0.00 | 7.62M | 20.55M | 49.56M | 27.73M | 6.86M | 2.74M | 792.00K | 95.00K | 0.00 |
| SG&A | 29.94M | 31.63M | 29.15M | 41.35M | 72.78M | 47.57M | 22.19M | 15.76M | 10.60M | 5.82M | 5.01M |
| Other Expenses | 0.00 | -102.00K | -174.00K | -311.00K | -511.00K | -321.00K | 176.00K | 25.00K | 26.00K | 0.00 | 0.00 |
| Operating Expenses | 78.69M | 71.35M | 56.37M | 61.76M | 111.21M | 79.43M | 52.93M | 42.11M | 28.85M | 18.70M | 18.80M |
| Cost & Expenses | 97.99M | 85.02M | 70.86M | 84.08M | 151.96M | 106.49M | 62.69M | 42.77M | 28.85M | 18.70M | 18.81M |
| Interest Income | 5.36M | 1.82M | 243.00K | 175.00K | 1.93M | 2.00M | 135.00K | 80.00K | 9.00K | 0.00 | 10.00K |
| Interest Expense | 11.11M | 18.70M | 16.72M | 16.17M | 12.20M | 8.28M | 3.10M | 1.60M | 1.10M | 191.00K | 0.00 |
| Depreciation & Amortization | 1.28M | 985.00K | 1.24M | 1.14M | 1.00M | 270.00K | 227.27K | 155.00K | 118.00K | 189.00K | 220.00K |
| EBITDA | -48.01M | 161.81M | -284.52M | -157.86M | -99.41M | -85.42M | -55.77M | -42.17M | -28.66M | -18.51M | -18.57M |
| EBITDA Ratio | -214.40% | -408.23% | -417.65% | -1,859.91% | -622.43% | -454.17% | -875.18% | -12,702.71% | -75,418.42% | 0.00% | -109,229.41% |
| Operating Income | -75.60M | -68.63M | -57.18M | -79.13M | -130.66M | -87.58M | -56.31M | -42.43M | -28.81M | -18.70M | -18.79M |
| Operating Income Ratio | -337.66% | -418.74% | -418.15% | -1,598.91% | -613.41% | -463.06% | -883.62% | -12,781.02% | -75,821.05% | 0.00% | -110,523.53% |
| Total Other Income/Expenses | 15.21M | 210.75M | -245.29M | -96.04M | 15.11M | -6.39M | -2.79M | -1.50M | -1.07M | -183.00K | 10.00K |
| Income Before Tax | -60.39M | 142.12M | -302.48M | -175.17M | -115.55M | -93.97M | -59.10M | -43.93M | -29.88M | -18.89M | -18.78M |
| Income Before Tax Ratio | -269.73% | 867.16% | -2,211.88% | -3,539.46% | -542.46% | -496.86% | -927.37% | -13,231.93% | -78,623.68% | 0.00% | -110,464.71% |
| Income Tax Expense | 0.00 | 18.70M | 15.31M | 15.86M | 10.69M | 6.39M | 2.79M | 1.50M | 1.07M | 183.00K | 0.00 |
| Net Income | -60.39M | 142.12M | -317.78M | -191.02M | -126.23M | -93.97M | -59.10M | -43.93M | -29.88M | -18.89M | -18.78M |
| Net Income Ratio | -269.73% | 867.16% | -2,323.81% | -3,859.85% | -592.62% | -496.86% | -927.37% | -13,231.93% | -78,623.68% | 0.00% | -110,464.71% |
| EPS | -0.11 | 0.30 | -0.75 | -0.84 | -0.67 | -0.60 | -0.51 | -0.49 | -0.33 | -9.89 | -24.66 |
| EPS Diluted | -0.11 | -0.11 | -0.75 | -0.84 | -0.67 | -0.60 | -0.51 | -0.49 | -0.33 | -9.89 | -24.66 |
| Weighted Avg Shares Out | 567.97M | 467.95M | 422.32M | 227.91M | 188.75M | 157.43M | 115.98M | 89.24M | 91.56M | 1.91M | 761.63K |
| Weighted Avg Shares Out (Dil) | 567.97M | 618.21M | 422.32M | 227.91M | 188.75M | 157.43M | 115.98M | 89.24M | 91.56M | 1.91M | 761.63K |
Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.04 per share a year ago.
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Tim Goodnow - President and Chief Executive Officer Rick Sullivan - Chief Financial Officer Brian Hansen -...
Senseonics to Host Virtual KOL Event on Eversense 365: FDA Clearance and Commercialization Plans for the World's First One-Year CGM System
Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with management Event featuring David T. Ahn, MD from Hoag Medical Group and Jeff Ciaramita, MD from Mercy health system, along with management
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older Commercial launch by Ascensia Diabetes Care underway with a new campaign...
Mercy Places First Commercial Eversense 365: The World's First and Only 365-Day Continuous Glucose Monitor
Senseonics' Eversense 365 is approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with Type 1 and Type 2 diabetes aged 18 and older
Eversense 365 Launches in the US: One Year. One CGM.
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ascensia Diabetes Care, a global diabetes care company, announces that it is launching the Eversense® 365 continuous glucose monitoring (CGM) system, the world's only One Year CGM, to people with diabetes in the U.S.ii Developed by Senseonics Holdings,...
Senseonics Stock Down Despite New FDA Approval for Eversense 365
SENS' latest regulatory clearance is likely to simplify diabetes management with the help of a long-lasting CGM system.
Eversense 365 Receives FDA Clearance: The World's First One Year CGM
Eversense 365 cleared in the U.S. as an integrated continuous glucose monitoring (iCGM) system for people with diabetes
Senseonics Holdings, Inc. to Participate in the Upcoming H.C. Wainwright 26th Annual Global Investment Conference
GERMANTOWN, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to...
Senseonics Holdings, Inc. Provides Business Update and Full Year 2024 Financial Outlook
GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced business updates and provided its full year 2024...
Source: https://incomestatements.info
Category: Stock Reports